1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

TAK
Takeda Pharmaceutical Company LimitedUS flagNew York Stock Exchange
17.86
USD
- -
- -
56.83BMarket Cap
Takeda Pharmaceutical Company Limited
TAK
(New York Stock Exchange)

Recent

price

17.86

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
899.07
955.77
986.13
1,071.4
1,130.36
1,152.75
1,108.73
1,133.78
1,090.63
1,056.76
1,023.62
1,141.35
1,297.67
1,362.7
1,450.89
1,430.33
1,461.76
Revenue per Share
157.01
78.64
94.1
67.55
-92.69
51.13
73.58
119.67
70.3
14.21
120.36
73.57
102.14
46.04
34.18
-48.38
-51.72
Basic EPS, GAAP
128.44
168.19
139.54
44.46
46.92
-37.86
95.59
159.83
101.08
145.15
247.91
299.67
110.67
75.3
214.57
198.97
153.98
Free Cash Flow per Basic Share
89.98
89.95
90.01
90.02
90.05
90.27
90.7
90.86
74.34
90.73
90.7
90.71
90.03
91.79
95.8
99.01
52.73
Dividend per Share
2,650.11
2,669.22
2,880.58
3,129.63
2,719.26
2,487.04
2,425.92
2,556.51
3,332.94
3,032.22
3,308.93
3,643.88
4,087.49
4,635.57
4,407.01
4,702.66
4,782.57
Book Value per Share
2,003.71
630.96
588.09
659.27
478.13
544
-241.21
-58.99
-2,450.14
-2,221.39
-1,771.82
-1,630.72
-1,740.89
-1,536.94
-1,284.22
-1,138.67
-1,088.51
Tangible Book Value per Share
1,579
1,579
1,579
1,579
1,573
1,568
1,562
1,562
1,923
3,114
3,124
3,127
3,104
3,129
3,158
3,150
3,160
Basic Weighted Avg Shares
1,419,385
1,508,932
1,557,005
1,691,685
1,777,824
1,807,378
1,732,051
1,770,531
2,097,224
3,291,188
3,197,812
3,569,006
4,027,478
4,263,762
4,581,551
4,505,720
4,618,935
Sales/Revenue/Turnover
25.86
17.56
4.17
8.23
-7.27
7.24
5.66
10.56
9.17
8.71
13.06
15.3
14.6
7.27
10.18
10.31
10.42
Operating Margin (%)
106,722
150,194
247,206
215,743
260,951
197,381
171,426
182,127
247,691
583,649
559,671
583,151
664,400
728,002
761,396
721,127
650,419
Depreciation Expense
247,868
124,162
148,583
106,658
-145,775
80,166
114,940
186,886
135,192
44,241
376,005
230,059
317,017
144,067
107,928
-152,390
-163,436
Net Income, GAAP
32.65
49.59
- -
31.03
- -
30.74
19.42
14.04
- -
- -
- -
23.93
15.48
- -
38.23
- -
194.54
Effective Tax Rate (%)
17.46
8.23
9.54
6.3
-8.2
4.44
6.64
10.56
6.45
1.34
11.76
6.45
7.87
3.38
2.36
-3.38
-3.54
Profit Margin (%)
1,149,656
302,477
597,558
789,782
503,248
516,574
-105,930
341,299
439,988
293,534
939,717
447,912
-83,984
245,477
14,671
258,429
385,722
Working Capital
16,387
300,948
582,623
704,580
629,416
539,760
599,862
985,644
4,766,005
4,506,487
4,613,218
4,141,418
4,042,741
4,476,501
3,966,326
4,369,681
4,419,998
LT Debt
2,136,656
2,167,812
2,338,286
2,540,635
2,206,176
2,011,203
1,948,965
2,017,409
5,185,991
4,727,486
5,177,177
5,683,523
6,354,671
7,274,005
6,935,979
7,430,649
7,558,876
Total Equity
11.16
5.41
- -
2.95
- -
3.12
2.64
5.15
- -
- -
- -
4.12
4.69
- -
2.42
- -
- -
Return on Invested Capital (%)
11.35
5.01
- -
3.95
- -
3.46
4.1
6.42
- -
- -
- -
3.26
4.01
- -
1.63
- -
2.98
Return on Capital (%)
11.77
5.91
6.78
4.5
-6.33
3.92
5.98
9.6
3.77
0.89
7.6
4.24
5.27
2.11
1.52
-2.12
-2.27
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
583,147
512,157
519,970
LT Borrowings
4,270,174
4,369,681
4,419,998
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,580
1,580
1,580
Market Capitalization
3,859,255
4,645,694
4,119,513

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
3,116,439
3,090,503
3,150,269
Cash, Cash Equivalents & STI
761,941
636,942
527,582
Accounts Receivable, Net
736,464
977,355
930,377
Inventories
1,407,192
1,396,620
1,447,259
Total Current Liabilities
2,610,183
2,832,074
2,764,547
Payables & Accruals
615,930
589,225
564,715
ST Debt
583,147
512,157
519,970
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.67%
7.71%
7.13%
Free Cash Flow
0.37%
21.26%
-7.5%
Net Income, GAAP
43.91%
-64.37%
-241.2%
Sales/Revenue/Turnover
10.67%
7.22%
-1.66%
Total Cash Common Dividend
10.88%
1.97%
3.11%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,207,990
1,176,038
1,144,124
1,053,399
4,581,551
2026
1,106,685
1,112,796
1,191,698
1,094,541
4,505,720
2027
1,219,900
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
30.35
- -
- -
- -
34.18
2026
39.7
- -
- -
- -
-48.38
2027
35.82
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
44.01
- -
- -
- -
95.8
2026
46.43
- -
- -
- -
99.01
2027
- -
- -
- -
- -
- -
Similar Companies
MariMed Inc. (MRMD)
North Bud Farms Inc. (NOBDF)
Alembic Pharmaceuticals Limited (APLLTD.BO)
Cardiol Therapeutics Inc. (CRDL.TO)
Medcolcanna Organics Inc. (MCCNF)
Stenocare A/S (STENO.CO)
Business
Takeda Pharmaceutical Company Limited operates globally, dedicated to the research, development, production, and commercialization of innovative biopharmaceutical treatments. The company focuses its scientific efforts and delivers therapies across several key areas: gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Its portfolio includes prominent brands such as Entyvio for inflammatory bowel diseases, Vyvanse for ADHD, and Takhzyro for rare genetic conditions, alongside various other products for oncology and plasma-derived needs. With operations spanning approximately 80 countries and regions worldwide, Takeda maintains a significant presence across Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific. The company actively engages in strategic alliances and licensing agreements to advance its pipeline and expand its market reach. Recent collaborations include a notable $11.4 billion deal with China's Innovent Biologics in October 2025 to accelerate immuno-oncology and antibody-drug conjugate cancer therapies. Additionally, Takeda expanded its partnership with Beacon Biosignals in November 2025 to further narcolepsy diagnosis and neurobiomarker discovery. The company also received FDA approval for Eohilia, an oral treatment for allergic inflammation of the esophagus, in February 2024. Founded in 1781, Takeda is headquartered in Tokyo, Japan, and remains a leading global biopharmaceutical firm driven by a patient-centric approach and commitment to sustainable healthcare solutions. It consistently invests substantially in research and development, with a robust late-stage pipeline aimed at delivering life-transforming medicines.

Company News

Company News APIChatGPT

  • defenseworld.net

    Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Takeda Pharmaceutical (NYSE:TAK)

  • defenseworld.net

    Takeda Pharmaceutical (NYSE:TAK) vs. RYTHM (NASDAQ:RYM) Financial Survey

  • businesswire.com

    Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

  • businesswire.com

    Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

  • reuters.com

    Roche proposes former Takeda CEO for board seat

  • businesswire.com

    Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

  • businesswire.com

    Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

  • reuters.com

    India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

  • defenseworld.net

    Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast

  • seekingalpha.com

    Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • zacks.com

    Best Value Stocks to Buy for September 14th

  • zacks.com

    Best Income Stocks to Buy for September 14th

  • businesswire.com

    U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

  • businesswire.com

    Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026

  • businesswire.com

    New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

  • defenseworld.net

    Critical Survey: ABVC BioPharma (NASDAQ:ABVC) vs. Takeda Pharmaceutical (NYSE:TAK)

  • zacks.com

    Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

  • businesswire.com

    Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

  • cnbc.com

    Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

  • businesswire.com

    Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera